Lehrstuhl für Geburtshilfe und Frauenheilkunde

RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A Post Hoc Analysis of the GeparOLA Trial (2025) Villacampa G, Llop-Guevara A, Filmann N, Herencia-Ropero A, Fasching P, Karn T, Marmé F, et al. Journal article A Swedish genome-wide haplotype association analysis identifies novel candidate loci associated with endometrial cancer risk (2025) Barnekow E, Liu W, Andersson E, Wang X, Helgadottir HT, Thutkawkorapin J, Barilla S, et al. Journal article Cell-free tumor DNA analysis in advanced or metastatic breast cancer patients: mutation frequencies, testing intention, and clinical impact (2025) Hübner H, Wimberger P, Laakmann E, Ruckhäberle E, Rübner M, Lehle S, Uhrig S, et al. Journal article The Role of Artificial Intelligence in Gynecologic Oncology Decision-Making: A Feasibility Study (2025) Psilopatis I, Sipulina N, Stübs F, Heindl F, Pöschke P, Bader S, Krückel A, et al. Journal article Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping (2025) Denkert C, Rachakonda S, Karn T, Weber K, Martin M, Marmé F, Untch M, et al. Journal article Low-dose Oral Misoprostol after Cervical Ripening with a Double-balloon Catheter: 25 µg or 50 µg? (2025) Kehl S, Karademir ZS, Weiss C, Titzmann A, Schneider M, Beckmann M, Bader S Journal article Genome-Wide Association Analyses of HPV16 and HPV18 Seropositivity Identify Susceptibility Loci for Cervical Cancer (2025) Beckhaus T, Kachuri L, Nakase T, Schürmann P, Eisenblätter R, Geerts M, Böhmer G, et al. Journal article Prognostic Significance of the Detection of Human Papilloma Virus L1 Protein in Smears of Cervical Intraepithelial Neoplasia Grade 3 in Pregnant Women (2025) Stübs F, Dietl A, Schulmeyer C, Behrens A, Seibold A, Brückner L, Schleicher O, et al. Journal article PD-L1-Expression in in primary and recurrent vulvar squamous cell cancer (2025) Stübs F, Knöll A, Hartmann A, Leikauf LS, Matek C, John N, Häberle L, et al. Journal article A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial (2025) Hortobagyi GN, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, Hee Park Y, et al. Journal article